376 related articles for article (PubMed ID: 17302189)
1. Prevention and early detection of ovarian cancer: mission impossible?
Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
[TBL] [Abstract][Full Text] [Related]
2. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
3. Early detection of ovarian cancer.
Badgwell D; Bast RC
Dis Markers; 2007; 23(5-6):397-410. PubMed ID: 18057523
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
5. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
6. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
[TBL] [Abstract][Full Text] [Related]
7. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
Bast RC
Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
[TBL] [Abstract][Full Text] [Related]
8. Molecular approaches to prevention and detection of epithelial ovarian cancer.
Bast RC; Boyer CM; Xu FJ; Wiener J; Dabel R; Woolas R; Jacobs I; Berchuck A
J Cell Biochem Suppl; 1995; 23():219-22. PubMed ID: 8747399
[TBL] [Abstract][Full Text] [Related]
9. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.
Hogg R; Friedlander M
J Clin Oncol; 2004 Apr; 22(7):1315-27. PubMed ID: 15051780
[TBL] [Abstract][Full Text] [Related]
10. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
[TBL] [Abstract][Full Text] [Related]
12. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
[TBL] [Abstract][Full Text] [Related]
13. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
[TBL] [Abstract][Full Text] [Related]
14. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
15. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
Rosenthal AN; Fraser L; Manchanda R; Badman P; Philpott S; Mozersky J; Hadwin R; Cafferty FH; Benjamin E; Singh N; Evans DG; Eccles DM; Skates SJ; Mackay J; Menon U; Jacobs IJ
J Clin Oncol; 2013 Jan; 31(1):49-57. PubMed ID: 23213100
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
17. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
18. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
19. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
[TBL] [Abstract][Full Text] [Related]
20. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
